EBR Systems (ASX:EBR) said its manufacturing pre-approval inspection with the US Food and Drug Administration has been set for the week starting Jan. 6, 2025, according to a Thursday filing with the Australian bourse.
The inspection aims to confirm that the company's manufacturing, processing, and packing procedures adhere to quality system regulations, ensuring consistent device production meeting approved specifications, the filing said.
The US FDA initiated a review for the company's pre-market approval submission in late September, with the upcoming day-100 meeting scheduled for Friday, according to the filing.
Shares rose nearly 3% in midday trade Thursday.
Price (AUD): $0.89, Change: $+0.03, Percent Change: +2.91%
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。